Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHOCARBAMOL AND ASPIRIN vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is unknown but may involve general CNS depression. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Adjunct to rest, physical therapy, and other measures for relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: relief of muscle spasm in tetanus (methocarbamol component)
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
1 to 2 tablets (methocarbamol 400 mg / aspirin 325 mg per tablet) orally every 4-6 hours as needed, not to exceed 6 tablets per day.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Methocarbamol: 1–2 hours (terminal). Aspirin: 15–20 minutes for parent drug; salicylic acid: 2–3 hours (low doses) to 15–30 hours (high doses, due to saturable metabolism). Combined product: consider aspirin's longer terminal half-life at therapeutic doses.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Methocarbamol is metabolized via dealkylation and hydroxylation, primarily by CYP450 enzymes (CYP2C9, CYP1A2, CYP2D6) and undergoes Phase II conjugation. Aspirin is rapidly hydrolyzed to salicylic acid by esterases in plasma and liver; salicylic acid is primarily conjugated with glycine (salicyluric acid) and glucuronic acid, with minor oxidation.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Methocarbamol: Renal excretion of glucuronide and sulfate conjugates (95%) with <5% unchanged. Aspirin: Renal excretion of salicylic acid and metabolites (primarily salicyluric acid and glucuronides) with ~50% as salicylate at alkaline p H; biliary elimination <5%.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Methocarbamol: 46–50% (mainly albumin). Aspirin: 80–90% (albumin; salicylate binding is concentration-dependent, 50–90%).
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
Methocarbamol: 0.7–0.8 L/kg (distributes into total body water). Aspirin: 0.15–0.2 L/kg for salicylate at therapeutic doses, increasing to >0.3 L/kg at toxic levels (tissue accumulation).
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Methocarbamol: Oral bioavailability ~100% (well absorbed). Aspirin: Oral bioavailability 40–50% (first-pass hydrolysis to salicylate; enteric-coated forms may have delayed absorption).
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
Cr Cl <50 m L/min: avoid aspirin component (risk of accumulation and toxicity). Methocarbamol may require cautious use with monitoring. Cr Cl <30 m L/min: contraindicated (aspirin); methocarbamol not recommended.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
Child-Pugh Class A: no change. Child-Pugh Class B: reduce dose by 50% or prolong interval. Child-Pugh Class C: contraindicated (risk of bleeding and hepatotoxicity).
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Not recommended in children <12 years due to aspirin's risk of Reye's syndrome. For ≥12 years: same as adult (1-2 tablets every 4-6 hours, max 6 tablets/day).
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Elderly patients: start with lowest dose (1 tablet every 6 hours) due to increased sensitivity and higher risk of bleeding with aspirin; monitor renal function and consider avoiding chronic use.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
Reye's syndrome: Aspirin should not be used in children or teenagers with viral infections due to risk of Reye's syndrome.
None
Salicylate toxicity (tinnitus, hyperventilation, metabolic acidosis); bleeding risk (aspirin antiplatelet effect); hepatic impairment; renal impairment; GI bleeding; pregnancy (avoid in third trimester); nursing mothers; hypersensitivity to NSAIDs; concomitant use of methotrexate or anticoagulants; Reye's syndrome risk in pediatric viral illness.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Hypersensitivity to methocarbamol, aspirin, or any component; children and teenagers with or recovering from viral illness (Reye's syndrome); third trimester of pregnancy; bleeding disorders (e.g., hemophilia); active peptic ulcer; severe renal impairment; concomitant use of methotrexate (≥15 mg/week) or oral anticoagulants (relative).
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Avoid alcohol (increases CNS depression and GI bleeding risk). Take with food or milk to minimize gastric irritation. Avoid high-dose vitamin C or acidic foods that may increase aspirin absorption and toxicity.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
First trimester: Aspirin is associated with increased risk of miscarriage and congenital malformations (e.g., gastroschisis) at high doses; methocarbamol has limited data, but no major teratogenicity reported. Second trimester: Aspirin may cause premature closure of ductus arteriosus at high doses; methocarbamol safety uncertain. Third trimester: Aspirin increases risk of intracranial hemorrhage in neonate and premature closure of ductus arteriosus; avoid use after 30 weeks. Methocarbamol: no known specific fetal risks, but avoid in late pregnancy due to potential maternal muscle relaxation effects.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Aspirin is excreted into breast milk with an M/P ratio of 0.6-1.0; potential for Reye syndrome or platelet dysfunction in infant at high doses. Methocarbamol excretion unknown; no adverse effects reported. Use with caution, especially with high-dose aspirin.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
No specific pharmacokinetic changes reported for methocarbamol in pregnancy. For aspirin, increased renal clearance in pregnancy may require higher doses for anti-inflammatory effect, but doses >325 mg/day are avoided due to fetal risks. Use lowest effective dose, not exceeding 100 mg/day in third trimester.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Methocarbamol is a centrally acting muscle relaxant; aspirin is an NSAID. Onset of methocarbamol is rapid (30 min) with peak at 2 hours. Aspirin component may increase bleeding risk, especially with alcohol or anticoagulants. Avoid in children with viral illness due to Reye's syndrome risk. Max aspirin dose 4g/day.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Take with food to reduce GI upset.,Avoid alcohol and other CNS depressants.,May cause drowsiness or dizziness; avoid driving.,Do not use in children or teenagers with chickenpox or flu symptoms.,Stop and seek medical attention if signs of bleeding or allergic reaction occur.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
"The coadministration of propofol, a GABA-A receptor agonist general anesthetic, with methocarbamol, a centrally acting muscle relaxant, can produce additive sedative and respiratory depressant effects. This interaction may lead to excessive sedation, prolonged recovery from anesthesia, and an increased risk of hypoxia or apnea. Clinically, patients may exhibit deeper levels of unconsciousness and require prolonged monitoring of respiratory function."
"Methocarbamol, a centrally acting muscle relaxant, potentiates the sedative effects of nabilone, a synthetic cannabinoid used for chemotherapy-induced nausea and vomiting. This additive central nervous system depression can lead to excessive drowsiness, dizziness, impaired motor coordination, and increased risk of falls or cognitive impairment. Clinically, patients may experience exacerbated sedation, confusion, and psychomotor slowing, particularly when initiating therapy or at higher doses."
"Concomitant use of methocarbamol and gabapentin enacarbil results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic neurotransmission and neuronal excitability. This synergistic interaction significantly increases the risk of excessive sedation, dizziness, and impaired psychomotor function, potentially leading to falls, cognitive deficits, or respiratory depression in susceptible patients. Clinical outcomes are dose-dependent and more pronounced in elderly patients or those with pre-existing CNS compromise."
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHOCARBAMOL AND ASPIRIN vs CARISOPRODOL COMPOUND, answered by our medical review team.
METHOCARBAMOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is unknown but may involve general CNS depression. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHOCARBAMOL AND ASPIRIN and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHOCARBAMOL AND ASPIRIN is: 1 to 2 tablets (methocarbamol 400 mg / aspirin 325 mg per tablet) orally every 4-6 hours as needed, not to exceed 6 tablets per day.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining METHOCARBAMOL AND ASPIRIN and CARISOPRODOL COMPOUND. The risk or severity of adverse effects can be increased when Carisoprodol is combined with Methocarbamol. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. METHOCARBAMOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin is associated with increased risk of miscarriage and congenital malformations (e.g., gastroschisis) at high doses; methocarbamol has limited data, but no m. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.